Myeloma cells can promote osteoclastic activity rather than osteoclast recruitment in vitro; Evidence from the 5T2MM murine model of myeloma

Myeloma cells can promote osteoclastic activity rather than osteoclast recruitment in vitro; Evidence from the 5T2MM murine model of myeloma

Podrobná bibliografie
Hlavní autoři:	Mueller, G, Vanderkerken, K, Russell, R, Croucher, P
Médium:	Conference item
Vydáno:	2004

Podobné jednotky

5T2MM murine myeloma cells and CD138+ve human myeloma cells promote osteoclastic activity rather than osteoclast formation in vitro
Autor: Mueller, G, a další
Vydáno: (2004)

The Role of Myeloma Cells to Osteoclast Activation
Autor: Bahare Sadeghi, a další
Vydáno: (2010-01-01)

Glycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease
Autor: Ersek, A, a další
Vydáno: (2015)

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.
Autor: Shipman, C, a další
Vydáno: (2000)

An In Vitro Model of Murine Osteoclast-Mediated Bone Resorption
Autor: Xiaoyue Sun, a další
Vydáno: (2024-11-01)

Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.
Autor: Edwards, C, a další
Vydáno: (2007)

Translational potential of a novel osteoclast inhibitor, eliglustat, in myeloma bone disease
Autor: Leng, H
Vydáno: (2019)

Interleukin-32 promotes osteoclast differentiation but not osteoclast activation
Autor: Mabilleau, G, a další
Vydáno: (2009)

Interleukin-32 promotes osteoclast differentiation but not osteoclast activation.
Autor: Mabilleau, G, a další
Vydáno: (2009)

APOMINE (TM), a novel inhibitor of the meyalonate/isoprenoid pathway, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of the myeloma disease in vivo.
Autor: Croucher, P, a další
Vydáno: (2002)

Osteoprotegerin and the development of myeloma bone disease
Autor: Croucher, P, a další
Vydáno: (2004)

Zoledronic Acid Inhibits the Capacity of Myeloid-Immune Suppressor Cells in Myeloma to Form Osteoclasts.
Autor: Zhuang, J, a další
Vydáno: (2008)

CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
Autor: Dongzheng Gai, a další
Vydáno: (2022-09-01)

Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1
Autor: Yu-Tzu Tai, a další
Vydáno: (2018-08-01)

Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells
Autor: Tibullo eDaniele, a další
Vydáno: (2015-10-01)

Bisphosphonates and in vivo models of multiple myeloma - Reply
Autor: Shipman, C, a další
Vydáno: (2001)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
Autor: Croucher, P, a další
Vydáno: (2000)

Bisphosphonates--mechanisms of action in multiple myeloma.
Autor: Shipman, C, a další
Vydáno: (2000)

The checkpoint inhibitor PD-1H/VISTA controls osteoclast-mediated multiple myeloma bone disease
Autor: Jing Fu, a další
Vydáno: (2023-07-01)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
Autor: Croucher, P, a další
Vydáno: (2003)

BISPHOSPHONATES AFFECT HUMAN OSTEOCLAST DEVELOPMENT IN VITRO
Autor: Mabilleau, G, a další
Vydáno: (2010)

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
Autor: Vanderkerken, K, a další
Vydáno: (2003)

Osteoclasts in myeloma are derived from Gr-1+CD11b+mononuclear cells of the bone marrow niche
Autor: Zhuang, J, a další
Vydáno: (2007)

Osteoclasts in multiple myeloma are derived from Gr-1+CD11b+myeloid-derived suppressor cells
Autor: Zhuang, J, a další
Vydáno: (2012)

Glucose Ceramide Synthase Inhibitors Inhibit Osteoclast Activation Induced by Myeloma-Derived and De Novo Synthesized Glycosphingolipids
Autor: Xu, K, a další
Vydáno: (2009)

Multi-Scale Agent-Based Multiple Myeloma Cancer Modeling and the Related Study of the Balance between Osteoclasts and Osteoblasts.
Autor: Minna Qiao, a další
Vydáno: (2015-01-01)

A novel phthalimide derivative, TC11, has preclinical effects on high-risk myeloma cells and osteoclasts.
Autor: Maiko Matsushita, a další
Vydáno: (2015-01-01)

In vitro generation of mature human osteoclasts.
Autor: Hemingway, F, a další
Vydáno: (2011)

In vitro generation of mature human osteoclasts.
Autor: Hemingway, F, a další
Vydáno: (2011)

Isolation of human osteoclasts formed in vitro: hormonal effects on the bone-resorbing activity of human osteoclasts.
Autor: Kudo, O, a další
Vydáno: (2002)

Effect of amorphous silica nanoparticles on <it>in vitro </it>RANKL-induced osteoclast differentiation in murine macrophages
Autor: Nagano Kazuya, a další
Vydáno: (2011-01-01)

The Effects of Forodesine in Murine and Human Multiple Myeloma Cells
Autor: Liesbeth Bieghs, a další
Vydáno: (2010-01-01)

Osteoclasts and Microgravity
Autor: John Kelly Smith
Vydáno: (2020-09-01)

Estrogen receptor gene expression in osteoclasts loss with osteoclast maturation.
Autor: Oreffo, R, a další
Vydáno: (1997)

Osteoclast Activation and Inflammatory Bone Diseases: Focusing on Receptors in Osteoclasts
Autor: Zhao W, a další
Vydáno: (2025-03-01)

NK cells support osteoclast formation in vitro
Autor: Owen, S, a další
Vydáno: (2004)

Activated T lymphocytes support osteoclast formation in vitro.
Autor: Horwood, N, a další
Vydáno: (1999)

NK cells support osteoclast formation in vitro
Autor: Danks, L, a další
Vydáno: (2005)

The effects of seeding density and osteoclastic supplement concentration on osteoclastic differentiation and resorption
Autor: Stefan J.A. Remmers, a další
Vydáno: (2023-06-01)

Ewing's sarcoma cells promote osteoclast formation
Autor: Taylor, R, a další
Vydáno: (2010)